Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim
D-W
DW
Chung
Y-J
YJ
Lee
S
S
Kim
Y-J
YJ
Chung
N-G
NG
Kim
J A
JA
Oh
I-H
IH
Kim
T-G
TG
Kim
Y-L
YL
Goh
H-G
HG
Kim
S-H
SH
Cho
B
B
Kim
H-J
HJ
Min
C-K
CK
Lee
J W
JW
Jin
J Y
JY
Han
C-W
CW
Kim
J W
JW
Min
W-S
WS
Kim
H-K
HK
Kim
C-C
CC
Kim
H J
HJ
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases